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Cellular inhibitor of apoptosis proteins (cIAPs) block
apoptosis, but their physiological functions are still
under investigation. Here, we report that cIAP1 and
cIAP2 are E3 ubiquitin ligases that are required for
receptor-interacting protein 2 (RIP2) ubiquitination
and for nucleotide-binding and oligomerization
(NOD) signaling. Macrophages derived from Birc2/
orBirc3/ mice, or colonocytes depleted of cIAP1 or
cIAP2 by RNAi, were defective in NOD signaling and
displayed sharp attenuation of cytokine and chemo-
kine production. This blunted response was ob-
served in vivo when Birc2/ and Birc3/ mice
were challenged with NOD agonists. Defects in
NOD2 signaling are associated with Crohn’s disease,
and muramyl dipeptide (MDP) activation of NOD2
signaling protects mice from experimental colitis.
Here, we show that administration of MDP protected
wild-type but not Ripk2/ or Birc3/ mice from
colitis, confirming the role of the cIAPs in NOD2
signaling in vivo. This discovery provides therapeutic
opportunities in the treatment of NOD-dependent
immunologic and inflammatory diseases.
INTRODUCTION
Innate immunity serves as the first line of defense against
invading microbial pathogens by activating pathways that
mediate inflammation and pathogen clearance. Detecting path-
ogenic invasion and activating innate immune responses are
crucial for host survival. However, dysregulation of these path-
ways can lead to severe immunologic and inflammatory
diseases. Understanding the biochemical mechanisms that
regulate pathogen recognition, and the strength and duration
of the innate immune response, is therefore an important
priority.
The arsenal of innate immunity includes pattern recognition
receptors (PRRs) that sense conserved microbial componentscalled pathogen-associated molecular patterns (PAMPs) and
induce the initial antimicrobial response. PRRs include
membrane-bound Toll-like receptors (TLRs) that survey the
extracellular environment for pathogenic assault and cytosolic
nucleotide-binding and oligomerization domain (NOD)-like
receptors (NLRs) that function as intracellular sentinels. NOD1
(CARD4) and NOD2 (CARD15) proteins act as cytosolic PRRs
for bacterial peptidoglycan and are essential regulators of both
innate and adaptive immunity (Tattoli et al., 2007). NOD1 confers
responsiveness to peptidoglycan found primarily in Gram-nega-
tive bacteria, which contains meso-diaminopimelic acid (DAP),
whereas NOD2 detects the peptidoglycan derivative muramyl
dipeptide MurNAc-L-Ala-D-isoGln (MDP) (Tattoli et al., 2007).
Similar to TLR ligands, NOD agonists are shed and recycled
during bacterial growth and infection. It is now established that
PRR pathways synergize in their response to pathogens. They
utilize a plethora of molecular effectors including adaptors,
kinases, E3 ubiquitin ligases, and proteases to transduce the
‘‘danger’’ signal (Kawai and Akira, 2007; Shaw et al., 2008; Sirard
et al., 2007). The complexity of crosstalk in innate immunity
extends beyond these interactions given that it has been recently
shown that the pathways activated downstream of NOD1 and
NOD2 are closely related to those activated by TNF receptors.
Because NOD receptors and TNFR1 use structurally and func-
tionally similar components, they may be subject to common
regulatory mechanisms and feed-forward interactions (Chen
et al., 2004; Hitotsumatsu et al., 2008; Kim et al., 2008; Kobaya-
shi et al., 2002; Kobayashi et al., 2005). Upon NOD1 or NOD2
stimulation, the receptor-interacting protein 2, RIP2, which is
also referred to as RICK, CARDIAK, and RIPK2 and is a RIP
family member that is homologous to RIP1, is conjugated with
K63 ubiquitin chains. Polyubiquitinated RIP2 then serves as
a scaffold for the binding of TAK1 and for the activation of the
MAPK and NF-kB pathways leading to cytokine, chemokine,
and antimicrobial peptide production (Hasegawa et al., 2008;
Park et al., 2007; Yang et al., 2007). Ubiquitination involves the
concerted action of an E1 ubiquitin-activating enzyme, an E2
ubiquitin-conjugating enzyme, and an E3 ubiquitin ligase.
Ubc13 and Uev1a form the E2 complex responsible for K63
ubiquitination of RIP2, but the obligate E3 ubiquitin ligase is still
under debate (Hasegawa et al., 2008; Yang et al., 2007).Immunity 30, 789–801, June 19, 2009 ª2009 Elsevier Inc. 789
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cIAPs Regulate the NOD Innate Immune ResponseIdentifying the physiological E3 ligases for RIP2 is an important
advancement with potentially important therapeutic implica-
tions.
Inhibitor of apoptosis proteins (IAPs) form a family of geneti-
cally conserved proteins characterized by the presence of 1-3
baculovirus IAP repeat (BIR) motifs. Previous studies have
shown that three family members (termed XIAP, cIAP1, and
cIAP2) are potent suppressors of cell death (Salvesen and
Duckett, 2002). XIAP, the most-studied IAP, inhibits apoptosis
by binding and inhibiting caspases, and it has been broadly
assumed that cIAP1 and cIAP2 block apoptosis through a similar
mechanism. However, recent structure-function analyses have
indicated that these IAPs are not direct caspase inhibitors, sug-
gesting that their antiapoptotic function must involve alternative
mechanisms (Eckelman and Salvesen, 2006). An interesting
feature of several IAPs, including cIAP1 and cIAP2, is the pres-
ence of a C-terminal RING-finger domain with E3 ubiquitin
ligase activity. We recently demonstrated that cIAP1 and
cIAP2 are key players in the TNFR1 signaling pathway that act
as K63 E3 ubiquitin ligases for RIP1 (Bertrand et al., 2008).
cIAP-mediated polyubiquination of RIP1 allows it to bind to
the prosurvival kinase TAK1 and facilitates activation of NF-kB
to promote cell survival.
The IAPs play a critical role in innate immunity signaling in
Drosophila. Flies express two IAPs and one of these, dIAP2,
is required for innate immunity to Gram-negative bacteria (Ge-
sellchen et al., 2005; Kleino et al., 2005; Leulier et al., 2006;
Valanne et al., 2007). When flies are exposed to bacterial chal-
lenge, the PGRP-Lc receptor activates a signaling cascade
involving IMD, dTAB2, and dTAK1 (the fly orthologs of RIP1
and 2, TAB2 and 3, and TAK1, respectively) to activate JNK-
and NF-kB-dependent expression of genes encoding antimi-
crobial peptides. It is not certain whether K63 ubiquitination
of IMD is required for this response, but it seems likely given
that the Drosophila ortholog of Ubc13 is necessary for pathway
activation (Zhou et al., 2005). Epistasis analyses have placed
Ubc13 function at the level of IMD and placed dIAP2 down-
stream of IMD but upstream of TAB and TAK1 (Kleino et al.,
2005; Leulier et al., 2006). Therefore, it is likely that dIAP2
functions as an E3 ligase that targets IMD for K63-linked poly-
ubiquination.
In this report, we demonstrate that cIAP1 and cIAP2 function in
innate immunity signaling activated by NOD1 and 2 receptors.
We report that cIAP1 and cIAP2 are E3 ubiquitin ligases required
for K63 ubiquitination of RIP2. cIAP1 or cIAP2 null cells or cells
depleted of cIAP1 or cIAP2 by RNAi depletion showed profound
defects in RIP2-dependent activation of MAPK and NF-kB
signaling pathways in response to diaminopimelic acid (DAP)
or muramyl dipeptide (MDP), the NOD1 and NOD2 agonists,
and display sharp attenuation of NOD-dependent proinflamma-
tory cytokine and chemokine production. This blunted inflamma-
tory response translated in vivo to resistance of Birc2/ and
Birc3/ mice to peritonitis induced by NOD agonists and to
dampened serum cytokine titers. MDP activation of NOD2 has
been previously reported to protect mice from dextran sulfate
sodium (DSS) colitis (Watanabe et al., 2008) and we report
here that this protective effect was lost in Ripk2/ or Birc3/
mice. Together, our results demonstrate that cIAPs are key
regulators of NOD innate immunity signaling.790 Immunity 30, 789–801, June 19, 2009 ª2009 Elsevier Inc.RESULTS
cIAPs Regulate NOD1 and NOD2 Signaling Pathways
Leading to Cytokine and Chemokine Production
The RIP kinases have emerged as essential sensors of cellular
stress, integrating both extracellular signals emanating from
various cell-surface receptors and signals emerging from intra-
cellular pattern recognition receptors (Festjens et al., 2007).
Recent studies have highlighted the importance of RIP1 in TNF
receptor signaling, and we recently demonstrated an unex-
pected function for cIAP1 and cIAP2 as K63 ubiquitin ligases
for RIP1 (Bertrand et al., 2008).
TNFR1 and NOD1 and NOD2 receptors activate structurally
and functionally similar signaling components. We initially inves-
tigated whether cIAP1 and cIAP2 are part of the NOD1 signaling
complex by using an RNAi-based approach to deplete cIAP
expression in HT29 colonic cells. HT29 cells express NOD1
and signaling through this receptor can be activated with the
purified NOD1 agonist DAP (LeBlanc et al., 2008). We tested
whether cIAP1 or/and cIAP2 depletion had any effect on
NOD1-dependent cytokine and chemokine production.
Figure 1A shows that exposure of HT29 cells to the NOD1
agonist DAP induced expression of IL-8, TNFa, and MCP-1. As
expected, siRNA targeting of RIP2 almost completely blocked
the production of these factors. Remarkably, cIAP2 RNAi in-
hibited DAP-dependent induction of IL-8, TNFa, and MCP-1 to
the same extent as RIP2 depletion, whereas cIAP1 depletion
blocked the induction of TNFa and MCP-1 but had no effect
on IL-8 production (Figure 1A). To begin to decipher the relation-
ship between RIP2, cIAP1, and cIAP2, we investigated whether
cells depleted in these proteins by RNAi show similar defi-
ciencies in signaling pathways activated by NOD1. As previously
reported, DAP stimulation of NOD1 induced RIP2-dependent
activation of the MAP kinases p38 and JNK, as well as of the
transcription factor NF-kB, shown by the degradation of IkBa
(Figure 1B). Strikingly, repression of cIAP2 levels by RNAi pre-
vented DAP-dependent phosphorylation of JNK and p38 and
the degradation of IkBa (Figure 1C), whereas cIAP1 depletion
reduced DAP-dependent activation of JNK and NF-kB but had
no effect on p38 activation (Figure 1D). Taken together, our
results suggest that cIAP1 and cIAP2 function in NOD1 innate
immunity by regulating the signaling pathways leading to cyto-
kine and chemokine production.
To test the physiological relevance of this finding, we isolated
bone-marrow-derived macrophages (BMDM) from Birc2/ and
Birc3/ mice and compared their innate immune responses to
BMDMs derived from Ripk2/ or wild-type mice. DAP stimula-
tion of BMDMs did not induce production of cytokines and che-
mokines, probably because of the very low expression of Nod1
in these cells (data not shown). Nod2 is highly expressed in
BMDMs and Figure 2A shows that wild-type BMDMs responded
to MDP exposure by inducing production of IL-6, IL-1b, IL-10,
and TNFa, whereas Ripk2/, Birc2/, and Birc3/ macro-
phages were completely defective in MDP-dependent produc-
tion of these factors.
Birc3/ mice were reported to be resistant to lipopolysaccha-
ride (LPS)-induced septic shock, specifically because of an
attenuated inflammatory response (Conte et al., 2006). A synergy
between TLR and NOD receptor pathways has recently been
Immunity
cIAPs Regulate the NOD Innate Immune ResponseFigure 1. cIAP1 and cIAP2 Regulate RIP2-Dependent Innate Immune Response to the NOD1 Agonist DAP
(A) HT29 cells were transfected with siRNAs targeting cIAP1, cIAP2, RIP2, or nonspecific scramble RNA (NS) for 42 hr and were then left untreated or stimulated
with DAP (10 mg/ml) for 2 hr. RNA was extracted and IL-8, TNFa, and MCP-1 levels were measured by quantitative real-time PCR. Data represent average expres-
sion ± SEM from four independent experiments.
(B–D) HT29 cells were transfected as in (A) and exposed to DAP (10 mg/ml) for the indicated period, and cell lysates were immunoblotted as mentioned.established. MDP and LPS exert synergistic effects on cytokine
production, and pretreatment with MDP sensitizes mice to endo-
toxic shock induced by LPS injection (Takada et al., 2002). Many
preparations of bacterial components contain NOD1 and NOD2
agonists and using highly purified TLR ligands, Nunez and
colleagues ruled out a role for RIP2 in TLR signaling (Park
et al., 2007). To investigate whether LPS resistance in Birc3/
mice is mediated by a defect in NOD signaling, we treated
wild-type and Birc3/ BMDMs with MDP and LPS, alone or in
combination, and quantified IL-6 concentrations. Both wild-
type and Birc3/ macrophages produced equivalent amounts
of IL-6 in response to LPS treatment alone. At the low concentra-
tion of MDP used in this experiment, treatment with MDP alone
did not induce IL-6 production. However, when combined with
LPS, MDP greatly enhanced the production of IL-6 in wild-type
BMDMs but not in Birc3/ cells (Figure 2B). Together, these
data indicate that cIAP2 plays an obligate role in NOD2 signaling
but is dispensable for TLR4 signaling.
We then compared the signaling pathways activated by
MDP in wild-type, Ripk2/, Birc2/, and Birc3/ BMDMs.
Figure 2C shows that MDP-dependent activation of the MAPkinases p38 and JNK, and of the transcription factor NF-kB
(shown by the phosphorylation of IKKa/b and the degradation
of IkBa), did not occur in BMDMs derived from Ripk2/ mice.
Similarly, Birc2/ and Birc3/ BMDMs stimulated with MDP
showed strong attenuation of p38, JNK, and NF-kB compared
to wild-type cells (Figure 2D). Nod2 and Rip2 levels are unaf-
fected in Birc2/ and Birc3/ macrophages (Figures 2D and
2E) and we conclude that cIAP1, cIAP2, and RIP2 lie in the
same NOD-activated signaling path.
cIAP1 and cIAP2 Physically Interact with RIP2
NOD1 and NOD2 have a caspase recruitment domain (CARD) in
their N-terminal regions, a central nucleotide-binding and oligo-
merization domain (NOD), and a C-terminal leucine-rich repeat
domain (LRR). RIP2 is composed of N-terminal kinase and
C-terminal CARD domains linked via an intermediate region,
and it physically associates with NOD1 and NOD2 through
CARD-CARD interactions. cIAP1 and cIAP2 are composed of
three baculovirus IAP repeat (BIR) domains followed by
a CARD and a RING finger domain. We tested whether cIAP1
and cIAP2 directly bind RIP2 by performing pull-downImmunity 30, 789–801, June 19, 2009 ª2009 Elsevier Inc. 791
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cIAPs Regulate the NOD Innate Immune ResponseFigure 2. cIAP1 and cIAP2 Mediate RIP2-Dependent Innate Immune Response to the NOD2 Ligand MDP
(A) BMDMs isolated from wild-type, Ripk2/, Birc2/, and Birc3/ mice were left untreated or stimulated with MDP (100 mg/ml) for 2 hr, RNA was extracted,
and IL-6, TNFa, IL-1b and IL-10 levels were measured by quantitative real-time PCR. Data represent average expression ± SEM from three independent exper-
iments.
(B) Wild-type and Birc3/ BMDMs were left untreated or stimulated for 2 hr with MDP (10 ug/ml) and LPS (1 mg/ml) added either alone or together, RNA was
extracted, and IL-6 production was measured by quantitative real-time PCR. Data represent average expression ± SEM from four experiments.
(C and D) Wild-type, Ripk2/, Birc2/, and Birc3/ BMDMs were stimulated with MDP (100 mg/ml) for the periods indicated, and cell lysates were immuno-
blotted as mentioned.
(E) Immunoblot showing that Nod2 expression is not affected in Birc2 (c1/)- or Birc3 (c2/)- deficient BMDMs.experiments using bacterially produced GST-cIAP1 and GST-
cIAP2 fusion proteins and in vitro-transcribed and -translated
RIP2 labeled with 35S-Methionine. Figure 3A shows that RIP2
does not bind GST alone but does interact with GST-cIAP1
and GST-cIAP2. To address whether binding occurs through
CARD-CARD interactions, we transfected HEK293T cells with
cIAPs and RIP2 deletion mutants. A RIP2 mutant lacking the
CARD domain (RIP2DCARD), but not the CARD-only mutant
(CARD), coimmunoprecipitated full-length cIAP2 (FL), indicating
that RIP2 binds cIAP2 independently of its CARD domain
(Figure 3B). We next mapped the regions of cIAP2 involved in
RIP2 binding by using cIAP2 mutants containing either the BIR792 Immunity 30, 789–801, June 19, 2009 ª2009 Elsevier Inc.domains (BIR) or the CARD-RING portion of the protein
(CARD-RING). We found that both fragments could bind full-
length RIP2, indicating a two-site interaction (Figure 3B). Inter-
estingly, expression of full-length RIP2 consistently increased
levels of cIAP2 and cIAP2 fragments. In a similar set of experi-
ments, we found that full-length cIAP1, or a mutant containing
the BIR domains, coimmunoprecipitated full-length RIP2 but
not the CARD-only mutant (Figure 3C), indicating that cIAP1
does not rely on a CARD-CARD interaction to bind RIP2.
RIP2, cIAP1, or cIAP2 deletion causes similar defects in innate
immune responses and experiments above show that RIP2
binds to both cIAP1 and cIAP2. These findings raised the
Immunity
cIAPs Regulate the NOD Innate Immune ResponseFigure 3. cIAP1 and cIAP2 Bind RIP2 through a Non-CARD-CARD Interaction
(A) In vitro-transcribed and -translated RIP2 labeled with 35S-Methionine (Input) was incubated overnight with bacterially produced GST, GST-cIAP1, or GST-
cIAP2 bound to Sepharose beads. The beads were washed extensively and ran on an acrylamide gel, and RIP2 binding was revealed by autoradiography
(Pull-down).
(B) We analyzed the mapping of cIAP2-RIP2 interaction in HEK293T cells by coexpressing Flag-tagged RIP2 and Myc-tagged cIAP2 deletion mutants. RIP2 was
immunoprecipitated with a Flag antibody and coimmunoprecipitated cIAP2 was revealed by immunoblotting with a Myc antibody.
(C) The mapping of cIAP1-RIP2 interaction was analyzed in HEK293T cells by coexpressing Flag-tagged RIP2 and Myc-tagged cIAP1 deletion mutants. cIAP1
was immunoprecipitated with a Myc antibody and coimmunoprecipitated RIP2 was revealed by immunoblotting with a RIP2 antibody. Expression of exogenous
RIP2 in the lysate was monitored with a Flag antibody.
(D) HEK293T cells were transfected with the indicated plasmids and RIP2 was immunoprecipitated using a Myc antibody. Coimmunoprecipitated cIAP1, cIAP2
and FLAG-NOD2 were revealed by immunoblotting. For (B)–(D), RIP2 indicates full-length RIP2, RIP2DCARD indicates RIP2 mutant lacking the CARD domain,
CARD indicates the CARD only RIP2 mutant, and CIAP1* and CIAP2* refer to forms of cIAP1 and cIAP2 lacking E3 ligase activity.
(E) HT29 cells were transfected with siRNAs targeting cIAP1 (C1) or nonspecific scramble RNA (NS) and after 48 hr, endogenous cIAP2 was immunoprecipitated
and endogenous coimmunoprecipitated RIP2 was revealed by immunoblotting with a RIP2 antibody.possibility that a heteromeric complex of these proteins may be
required for normal signaling, as indicated by others (Rajalingam
et al., 2006). To test this, we transfected HEK293T cells with RIP2
and NOD expression plasmids in the presence and absence of
wild-type or RING-finger-mutated cIAP1 and cIAP2. Figure 3D
shows that NOD2, cIAP1, and cIAP2 can be coimmunoprecipi-
tated with RIP2 and that mutation of the RING domain enhancesthe association of cIAP1 and cIAP2 with RIP2. Expression of
cIAP1 or cIAP2 did not alter the coimmunoprecipitation of
NOD2 with RIP2, suggesting that the IAP-RIP2 and NOD2-
RIP2 interactions occur independently. We then investigated
whether a complex is formed between these proteins in HT29
cells, in which they are endogenously expressed. RIP2 and
cIAP2 can be coimmunoprecipitated from these cells, andImmunity 30, 789–801, June 19, 2009 ª2009 Elsevier Inc. 793
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cIAPs Regulate the NOD Innate Immune Responseinterestingly cIAP1 depletion reduces the amount of RIP2 protein
coimmunoprecipitated with cIAP2, suggesting that an oligo-
meric complex of cIAP1 and cIAP2 collaborate to bind RIP2 in
this cell type (Figure 3E). We also examined whether the subcel-
lular location of NOD2, RIP2, cIAP1, or cIAP2 was altered in HT29
cells treated with MDP or in transfected 293T cells but did not
observe translocation of these components in settings where
the NOD agonist activates NFkB and MAPK pathways and
induces cytokine and chemokine production (Figure S2 available
online and data not shown).
cIAP1 and cIAP2 Are E3 Ubiquitin Ligases Required
for K63 Ubiquitination of RIP2
A recent study has reported that RIP2 is conjugated with K63-
linked polyubiquitin chains at lysine 209 upon NOD1 or NOD2
activation (Hasegawa et al., 2008). This ubiquitination step is
crucial for activating the NOD-dependent immune response
because K63-ubiquitinated RIP2 serves as a scaffold that
assembles signaling complexes to activate the NF-kB pathway,
and presumably, the MAPK pathway. A20, a deubiquitinase
initially reported to remove K63-linked polyubiquitin chains on
RIP1 in the TNFR1 pathway, acts as a negative regulator of the
NOD2 immune response by editing RIP2-K63 ubiquitin chains
(Hasegawa et al., 2008; Hitotsumatsu et al., 2008). With an
RNAi-based approach, Ubc13-Uev1a was identified as the E2
component required for RIP2 ubiquitination (Yang et al., 2007),
but the physiological E3 ubiquitin ligase for RIP2 remained under
debate. We recently reported that Ubc13-Uev1a and cIAP1 and
cIAP2 function, respectively, as E2 and E3s for RIP1-K63 ubiqui-
tination in response to TNFR1 activation.
Hitotsumatsu and colleagues (2008) have shown that MDP-
induced RIP2 ubiquitination in BMDMs can only be detected in
an A20-deficient background because of the rapid editing of
RIP2 by A20. However, other groups have reported K63 ubiqui-
tination of RIP2 in HEK293 cells (Hasegawa et al., 2008; Yang
et al., 2007). We therefore tested whether cIAP1 and cIAP2 could
function as E3s for RIP2 by examining the effect of cIAP1 and
cIAP2 on RIP2 ubiquitination in transfected HEK293 cells.
TRAF6 has been suggested to function as an E3 for RIP2
(Yang et al., 2007), and we therefore used TRAF6 as a control
in these experiments. Surprisingly, expression of cIAP1 and
cIAP2 induced ubiquitination of RIP2 but expression of TRAF6
did not (Figure 4A). The stronger effect observed with cIAP2
may reflect the fact that cIAP1 is more difficult to overexpress
than cIAP2 (Figure S1). We next asked whether cIAP1 and
cIAP2 E3 ligase activity was required for RIP2 ubiquination.
Remarkably, cIAP1- and cIAP2-induced ubiquitination of RIP2
was not observed when RIP2 was coexpressed with E3 inactive
forms of the IAPs (Figure 4B). To determine the type of ubiquitin
chains the IAPs added to RIP2, we expressed RIP2 with wild-
type or mutant forms of ubiquitin that can only be K48 or K63
linked and found that RIP2 was conjugated with both K48 and
K63 polyubiquitin chains (Figure 4C). In HEK293T cells, RIP2 is
very weakly ubiquitinated when expressed by itself but is highly
ubiquinated when coexpressed with NOD2 (Figure 4D). We used
that property to test whether endogenous cIAP1 and cIAP2 in
HEK293T cells were required for NOD2-induced RIP2 ubiquina-
tion. Figure 4E shows that RNAi targeting cIAP1 or cIAP2 (C1 and
C2) reduced RIP2 ubiquitination, whereas nonspecific scram-794 Immunity 30, 789–801, June 19, 2009 ª2009 Elsevier Inc.bled siRNA (NS) did not. This effect was even more potent
when cIAP1 and cIAP2 RNAi were combined, suggesting a coop-
erative function for these IAPs (Figure 4E). Interestingly, endog-
enous cIAP2 protein levels are below our immunoblot detection
limit in HEK293T cells, but these experiments demonstrate that
the protein is expressed and is functional.
Together, our results demonstrate that cIAP1 and cIAP2 have
a physiological role in NOD innate immunity pathways, that their
E3 ligase activity is required for RIP2 ubiquitination, and that
cIAP1 and cIAP2 collaborate to regulate RIP2 signaling.
Birc2/ and Birc3/ Mice Exhibit a Blunted
Inflammatory Response to NOD Stimulation
We have shown that cIAP1 and cIAP2 participate in NOD biolog-
ical responses in murine macrophages and human intestinal
epithelial cells. To specifically investigate the role of these
proteins in NOD activation in vivo, we first challenged wild-
type, Ripk2/, Birc2/, and Birc3/ mice with intraperitoneal
injection of the purified Nod1 ligand DAP. IP injection of DAP or
synthetic NOD1 agonists (KF1B and FK156) has been shown to
stimulate chemokine production and neutrophil infiltration in the
peritoneum in wild-type but not in Nod1-deficient mice (Inohara
et al., 2003; Lysenko et al., 2007; Masumoto et al., 2006). We
therefore tested these parameters in the four mouse genotypes
under study. Intraperitoneal injection of DAP resulted in
a substantial release of the chemokines KC and MCP-1 and
the cytokine IL-6 in the bloodstream of wild-type mice 2 hr after
DAP injection (Figure 5A). This DAP response was blocked in
Ripk2/ mice and, interestingly, was also abrogated in Birc2/
and Birc3/ mice (Figure 5A). The impaired chemokine produc-
tion in Ripk2/, Birc2/, and Birc3/ mice translates into
profound defects in immune cell migration given that the recruit-
ment of neutrophils into the peritoneum 24 hr after DAP injection
was sharply reduced inRipk2/ andBirc3/ mice compared to
wild-type mice (Figure 5B), further confirming the requirement of
cIAPs in NOD1 signaling in vivo. Importantly, we also found that
IL-6 release in the bloodstream after IP injection of the NOD2
agonist MDP was abrogated in Ripk2/ and Birc3/ mice
compared to wild-type animals (Figure 5C), demonstrating that
cIAP proteins not only function in NOD1 signaling but is also
required for NOD2 signaling in vivo.
MDP Protects Wild-Type Mice, but Not Ripk2/
or Birc3/ Mice, from DSS Colitis
MDP administration protects mice from experimental colitis and
this protective effect is absent in mice with defective Nod2
signaling (Watanabe et al., 2008). To address the significance
of the role of the cIAP proteins in transducing NOD2 signaling
in vivo, we determined whether administration of MDP protects
mice from DSS colitis in the absence of cIAP function. In these
studies, wild-type, Ripk2/, or Birc3/ mice were treated
with 4% DSS from day 0 to day 5 and were administered MDP
(100 mg) or PBS, intra-peritoneally, for 3 consecutive days
beginning at the time of colitis induction (days 0, 1, and 2). As
shown in Figure 6A, DSS treatment induced drastic body weight
loss in wild-type mice treated with PBS (white squares) but not
those administered MDP (black squares). The protective effect
of MDP was absent in Ripk2/ mice because these mice ex-
hibited equivalent body weight loss in response to DSS colitis
Immunity
cIAPs Regulate the NOD Innate Immune ResponseFigure 4. cIAP1 and cIAP2 Are E3 Ubiquitin Ligases for K63 Ubiquitination of RIP2
(A) HEK293T cells were transfected for 42 hr with HA-Ubiquitin, Myc-tagged RIP2 and cIAP1, cIAP2, or TRAF6. RIP2 was immunoprecipitated and ubiquitinated
RIP2 was detected by immunoblotting as indicated.
(B) HEK293T cells were transfected for 42 hr with HA-tagged ubiquitin, Myc-tagged RIP2, and with E3 active (C1 and C2) or inactive (C1* and C2*) forms of cIAP1
and cIAP2, respectively. RIP2 was immunoprecipitated and ubiquitinated RIP2 was detected by immunoblotting as indicated.
(C) HEK293T cells were transfected for 42 hr with cIAP2 and wild-type (WT), K48-only (K48), or K63-only (K63) ubiquitin in the presence or absence of Myc-tagged
RIP2. RIP2 was immunoprecipitated and ubiquitinated RIP2 was detected by immunoblotting as indicated.
(D) HEK293T cells were transfected for 42 hr with HA-tagged ubiquitin, Myc-tagged RIP2, and Flag-tagged NOD2. RIP2 was immunoprecipitated and ubiquiti-
nated RIP2 was detected by immunoblotting as indicated.
(E) HEK293T cells were transfected with siRNAs targeting cIAP1 (C1), cIAP2 (C2), cIAP1+cIAP2 (C1+2), or nonspecific scramble RNA (NS) for 42 hr and with
Myc-tagged RIP2, Flag-tagged NOD2, and HA-tagged ubiquitin for the last 30 hr. RIP2 was immunoprecipitated and ubiquitinated RIP2 was detected by immu-
noblotting as indicated.Immunity 30, 789–801, June 19, 2009 ª2009 Elsevier Inc. 795
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cIAPs Regulate the NOD Innate Immune ResponseFigure 5. Defective NOD-Dependent Innate Immune Responses In Vivo in Birc2/ and Birc3/ Mice
(A) Wild-type,Ripk2/, Birc2/, and Birc3/ mice (n = 3/genotype/treatment) were injected intraperitoneally with DAP (2 mg/Kg) or endotoxin-free PBS. Blood
was collected from animals 2 hr after injection and KC, MCP-1, and IL-6 in the serum were measured with bead-based immunoassays.
(B) Wild-type, Ripk2/, and Birc3/ mice (n = 6 per genotype/treatment) were injected intraperitoneally with DAP (1 mg/kg) or endotoxin-free PBS. The number
of Gr1+ cells in the peritoneal lavage was quantified 24 hr later by FACS analysis. Averages are represented by straight bars.
(C) Wild-type,Ripk2/, andBirc3/ mice (n = 4 per genotype/treatment) were injected intraperitoneally with 25 mg/kg of MDP or endotoxin-free PBS. Blood was
collected from animals 4 hr after injection and IL-6 in the serum was measured by bead-based immunoassays. Error bars represent SEM.irrespective of whether they received MDP or PBS (white and
black circles). Furthermore, the MDP protective effect was
completely lost in mice deficient in ciap2 (white and black trian-
gles), strongly indicating a critical role of this protein in Nod2-
dependent biological responses in the gut. Figure 6B shows
that the body weight data correlated with expression of serum
amyloid A (SAA), an acute phase protein that reflects colitis
severity: wild-type mice treated with MDP had significantly lower
SAA amounts compared to PBS-treated controls (p = 0.001), and
no difference in SAA amounts was seen in Ripk2/ or Birc3/
mice treated with either PBS or MDP. Histological examination of
colon sections derived from wild-type, Rip2-, or ciap2-deficient
mice further supported the body weight loss and SAA measure-
ments, showing a conserved intestinal tissue architecture in
wild-type mice treated with DSS and MDP but not in DSS-
treated mice exposed to vehicle or in either Rip2- or ciap2-
deficient mice, which exhibited a severe colitis phenotype
characterized by loss of goblet cells, inflammatory infiltrates,
and intestinal epithelial lesions (Figure 6C). Altogether, these
data suggest that loss of cIAP2 function impairs the ability of
the NOD2-RIP2 complex to control colonic inflammation upon
systemic administration of MDP.
DISCUSSION
It has long been assumed that IAPs promote cell survival by
acting as direct caspase inhibitors. However, recent structure-796 Immunity 30, 789–801, June 19, 2009 ª2009 Elsevier Inc.function analysis revealed that, out of the eight IAPs found in
the human genome, XIAP is the only family member capable of
direct caspase inhibition (Eckelman and Salvesen, 2006). The
finding that a subset of IAPs contains a RING finger domain
with E3 ubiquitin ligase activity has implied the presence of alter-
native functions of these IAPs. We recently reported that cIAP1
and cIAP2 promote cancer cell survival by functioning as K63
ubiquitin ligases for RIP1, which allows RIP1 to activate the pro-
survival NF-kB pathway, while preventing it from binding to cas-
pase-8 and inducing apoptosis (Bertrand et al., 2008). This func-
tion appears to be evolutionarily conserved and physiologically
relevant as primary cultures of cells deficient in cIAPs are defec-
tive in TNF-induced NF-kB (Mahoney et al., 2008; Varfolomeev
et al., 2008). Similarly, the sole ciap family member expressed
in zebrafish maintains blood vessel integrity by facilitating the
formation of a TNFR complex I, promoting NF-kB activation
and preventing caspase-8-dependent apoptosis that leads to
vessel regression (Santoro et al., 2007). The TNFR signaling
pathway has similarities with the innate immune pathways acti-
vated by NOD1 and NOD2 receptors in mammals and by
PGRP-Lc receptor in the fly, given that they all lead to NF-kB
and MAP kinases activation using similar components.
Interestingly, in vivo and in vitro studies in Drosophila have
identified the fly IAP dIAP2 as an important regulator of the innate
immune response downstream of the PGRP-Lc receptor (Gesell-
chen et al., 2005; Kleino et al., 2005; Leulier et al., 2006; Valanne
et al., 2007), and available data suggest that dIAP2 may be a K63
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we demonstrate a physiological role for cIAP1 and cIAP2 as
regulators of innate immune signaling in mammals. We show
that these cIAPs function as E3 ubiquitin ligases required for
RIP2 ubiquitination that is induced by triggers that activate the
cytosolic PRRs NOD1 and NOD2. Taken together with other
recent findings, our data indicate that these IAPs function down-
stream of the TNFR1 and of the NOD1 and NOD2 receptors to
produce RIP1 ubiquination in the former and RIP2 ubiquination
in the latter.
RIP2 polyubiquitination is required for NOD-induced NF-kB
activation and subsequent cytokine and chemokine production
(Hasegawa et al., 2008; Hitotsumatsu et al., 2008), but the iden-
tity of the E3 ligase(s) that target RIP2 has been uncertain. RIP2
binds TRAF2, TRAF5, and TRAF6 proteins in vitro (McCarthy
et al., 1998), and some studies have suggested that these E3
ligases may mediate K63 ubiquitination of RIP1. For example,
Yang et al. (2007) showed that siRNA-mediated TRAF6 depletion
reduced NOD2-dependent RIP2 ubiquitination in HEK293T cells
and attenuated MDP-induced NF-kB activation in the RAW264.7
macrophage cell line. However, an earlier study from this group
reported that inhibition of TRAF6 expression had no effect on
NOD2-induced NF-kB activation in HEK293T cells, whereas
RIP2 repression greatly decreased it (Abbott et al., 2007). This
work is consistent with a recent report by Hasegawa et al.
(2008), who found that mouse embryonic fibroblasts (MEFs)
Figure 6. MDP Administration Prevents
DSS Colitis in Wild-Type but Not in Ripk2/
or Birc3/ Mice
Wild-type (n = 8), Ripk2/ (n = 6), and Birc3/
(n = 6) mice were treated with drinking water con-
taining 4% DSS for 6 days (day 0–5) and were
consequently given regular drinking water (DSS-
free) for an additional 3 days (day 6–8). On days
0, 1, and 2, mice were injected intraperitoneally
with either MDP (100 mg; 500 ml per mouse) or an
equivalent volume of endotoxin-free PBS, every
day.
(A) Body weight loss of mice treated with MDP or
PBS. Error bars represent SEM.
(B) Serum amyloid A (SAA) levels in the serum of
mice on day 8 were determined by ELISA. Error
bars represent SEM.
(C) H&E-stained colonic tissue sections of the
mice harvested on day 8. Original magnification
350 is shown.
deficient in Traf6 show normal NF-kB
activation upon Nod1 stimulation (Hase-
gawa et al., 2008).
Under conditions in which cIAP1 and
cIAP2 induce robust RIP2 ubiquitination,
TRAF6 did not. We, and others, have
previously shown that TRAF6 binds to
RIP2 and that TRAF6 is highly ubiquiti-
nated upon NOD activation (Abbott
et al., 2004; LeBlanc et al., 2008). It is
conceivable that the reduction of RIP2
ubiquitination observed by Yang et al.
(2007) in TRAF6-depleted cells represents a reduction in the
amount of polyubiquitinated TRAF6 coimmunoprecipitated
with RIP2. cIAP1 and cIAP2 were originally identified as
TRAF1- and TRAF2-binding partners (Rothe et al., 1995), and
one study shows that TRAF2 promotes the interaction of cIAP2
with RIP1 (Park et al., 2004). It is therefore possible that
TRAF2, TRAF5, and TRAF6 do not function as E3 enzymes tar-
geting RIP2 but rather serve as adaptor proteins that function
in a cell-specific manner to facilitate the interaction of cIAP1
and cIAP2 with RIP2. This may explain the requirement of
TRAF6, TRAF2, and TRAF5 for NOD-induced NF-kB activation
in RAW cells and MEFs.
cIAP1 and cIAP2 were originally identified as antiapoptotic
proteins, and we therefore determined whether they contribute
to viability in cells exposed to NOD ligands. NOD agonists had
no effect on the survival of wild-type, Birc2/, or Birc3/
BMDMs examined in vitro. Similarly, the survival of macro-
phages in the peritoneum of wild-type or Birc3/ mice was
not altered by MDP injection (data not shown).
The majority of polyubiquitin chains produced in vivo are either
K48 or K63 linkages and the fate of polyubiquitinated proteins is
in large part determined by the nature of these linkages. Gener-
ally, addition of K48 polyubiquitin chains allows recognition and
degradation by the proteasome, whereas K63 ubiquitination has
emerged as a key regulatory event that conveys signals from
receptors to intracellular kinase cascades. K63 ubiquitin chainsImmunity 30, 789–801, June 19, 2009 ª2009 Elsevier Inc. 797
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recruitment of the TAK1 kinase to the complex, and activation of
MAPK and NF-kB pathways. Upon cell stimulation, RIP1 is
initially K63 polyubiquitinated but with time, this is converted to
K48-linked polyubiquitination through the action of the A20
protein (Newton et al., 2008). Importantly, cIAP2 increases K48
and K63 ubiquitination of RIP2, and cells lacking cIAP1 or
cIAP2 fail to activate NOD-induced MAPK and NF-kB activation.
Previous studies from ourselves and others have demonstrated
that IAPs can function as K48 or K63 E3 ligases, depending on
target substrates and the availability of specific E2s (Bertrand
et al., 2008; Park et al., 2004). It is thus possible that cIAP1
and cIAP2 directly mediate K48 and K63 ubiquitination of
RIP2. Alternatively, the cIAPs may only induce K63 ubiquitina-
tion, which is subsequently edited to K48 by A20 or other
enzymes. The rapid K63 deubiquination of RIP2 controls the
duration and strength of inflammatory and antimicrobial
responses. Indeed, targeted gene deletion of either of the two
known K63 deubiquitinases, A20 and CYLD, results in uncon-
trolled inflammation and inflammatory bowel disease (Abbott
et al., 2007; Zhang et al., 2006).
The activities of cIAP1 and cIAP2 are largely, but not entirely,
overlapping. For example, in HT29 cells, knockdown of cIAP1
sharply reduced DAP-induced production of TNFa and MCP-1
but had no effect on IL-8 production. The depletion of cIAP2,
on the other hand, inhibited production of all three cytokines.
Correspondingly, p38 activation induced by DAP was blocked
by cIAP2 depletion but not by cIAP1 depletion, raising the possi-
bility that p38 activation is crucial for IL-8 mRNA production and/
or stabilization (Berube et al., 2009; Winzen et al., 1999). The
molecular basis for differences in downstream signaling activi-
ties supported by cIAP1 versus cIAP2 is not known at present.
However, it has been recently shown that regulation of p38 acti-
vation downstream of NOD signaling is distinct from that of
NF-kB and JNK pathways, in that it involves CARD9 and
MEKK4. Both Card9/ macrophages and Map3k4/ cells
(MEFs or T cells) show defective p38 activation in response to
Nod stimulation and retain normal NF-kB and JNK signaling
(Abell et al., 2005; Chi et al., 2005; Hsu et al., 2007). It will be
therefore important to explore whether cIAP1 and cIAP2 differ-
entially interact with CARD9 and MEKK4 to coordinate NOD
signaling. Intriguingly, a recent report has shown that mice lack-
ing the IAP family member Xiap are resistant to infection with
Listeria monocytogenes, raising the possibility that other IAPs
may participate in these pathways (Bauler et al., 2008).
Mutations in NOD1 and NOD2 genes are linked to inflamma-
tory bowel diseases and polymorphisms in the NOD2 gene are
tightly associated with Crohn’s disease (CD) and Blau’s
syndrome in human patients (Tattoli et al., 2007). The NOD2
polymorphisms in CD are believed to confer NOD2 loss of func-
tion, yet CD is associated with production of IL-1b, IL6, IL-12,
and TNFa, which are inflammatory cytokines derived from genes
that are strongly upregulated by NF-kB. Loss of NOD2 function
was hypothesized to result in bacterial overgrowth and sponta-
neous colitis, but Nod2-deficient mice do not show any sign of
spontaneous intestinal inflammation and therefore do not
support this hypothesis (Kobayashi et al., 2005). Chronic NOD
activation leads to tolerance and crosstolerance to bacterial
products in the intestine (Hedl et al., 2007; Kullberg et al.,798 Immunity 30, 789–801, June 19, 2009 ª2009 Elsevier Inc.2008), and NOD2 stimulation by MDP protects mice from exper-
imental colitis by attenuating TLR responses (Watanabe et al.,
2008). Therefore, an alternative hypothesis is that under normal
circumstances, NOD proteins regulate innate responses to
intestinal microflora by suppressing TLR responses and that
absence of this negative crossregulation increases susceptibility
to Crohn’s disease. Interestingly, in the DSS model of experi-
mental colitis, Birc3/ mice do not display the MDP-induced
protection that is observed in wild-type mice. This suggests
that IAPs may be part of a signaling complex that normally helps
balance innate immune signaling responses to intestinal micro-
flora. The identification of cIAP1 and cIAP2 as regulators of the
innate immune response provides new therapeutic opportunities
for the treatment of immunologic and inflammatory diseases.
EXPERIMENTAL PROCEDURES
Animal Strains
Birc2/, Birc3/, and Ripk2/ animals have been previously described
(Conte et al., 2006; Conze et al., 2005; Kobayashi et al., 2005). All these
mice lines were maintained in a pure C57Bl/6J genetic background and all
animal procedures were performed under guidelines of the animal ethics
committees of McGill University (Canada).
Reagents
Cell-culture supplies were obtained from Hyclone. Antibodies for pJNK (cat#
9255), pp38 (cat# 9211), p38 (cat# 9212), and pIKKa/b (cat# 2697) were
purchased from Cell Signaling Technologies and those for actin (cat# 69100)
were from MP Biomedicals. The monoclonal antibodies directed against ubiq-
uitin (cat# MMS-257P) and HA (cat# MMP-101P) were obtained from Covance;
polyclonal and monoclonal antibodies against RIP2 were obtained from Santa
Cruz Biotechnology (cat# sc-22763) and BD Bioscience (cat# 612349),
respectively. TRAF6 antibodies were obtained from Stressgen (cat# AAP-
426). The RIAP1 antibody used for detecting murine cIAP1 and cIAP2 was
previously described (Bertrand et al., 2008), and cIAP1- and cIAP2-specific
antibodies were obtained from R&D systems (cat# AF8171 and AF8181).
JNK1 (cat# sc-474) and IkBa (cat# sc-969) antibodies were purchased form
Santa Cruz Biotechnology; the Flag antibody was obtained from Sigma (cat#
F3165), and the 9E10 monoclonal antibody directed against Myc was
produced in the lab. Antibodies for NOD2 were obtained from D. Podolsky
(Harvard Medical School, USA). Secondary antibodies were obtained from
Jackson ImmunoResearch Laboratories. siRNA directed against human
cIAP1, cIAP2, and RIP2 and corresponding control RNAs were all Stealth
siRNAs purchased from Invitrogen Canada. siRNA targeting two distinct
regions of the mRNA were chosen and typically used in parallel experiment
together with matched controls. Specific siRNA sequences are available on
request. Tri-DAP, L-Ala-g-D-Glu-mDAP (cat# 60774), was from Anaspec;
and MDP, Ac-muramyl-Ala-D-Glu-NH2 (cat# G-1055), was from Bachem.
DOTAP transfection reagent (cat# 11 202 375 001) was from Roche, and
DSS, dextran sulfate sodium (MW 36,000-50,000), was from MP Biomedicals
(cat# 160110). The Milliplex kit for IL-6, KC, and MCP-1 was purchased from
Millipore (cat# MPXMCYTO-70K), and Serum Amyloid A (SAA) ELISA was
from Biosource (cat# KMA0011). The plasmid expressing Myc-tagged human
RIP2 was a kind gift from M. Chao (NYU School of Medicine, USA); those
encoding HA-tagged WT, K48, and K63 ubiquitin were obtained from Y. Zhang
(Howard Hughes Medical Institute, USA). We obtained Flag-tagged NOD2
construct by inserting a Flag sequence in frame with the human NOD2
sequence contained within a pCDNA3 plasmid originally produced by
G. Nunez (University of Michigan, USA). The E3 inactive forms of cIAP1 and
cIAP2 (producing H588A and H574A substitutions, respectively) were ob-
tained with a site-directed mutagenesis kit from Stratagene (cat# 200519-5)
and cloned, in parallel with the E3 active forms, into pDEST12.2. The plasmid
expressing Myc-tagged TRAF6 was kindly provided by S. Baksh (University of
Alberta, Canada). The construct expressing Flag-tagged RIP2 was a kind gift
of G. Nunez (University of Michigan); Flag-RIP2-CARD and Flag-RIP2-DCARD
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50-GCGG CTC GAG TTA CAT GCT TTT ATT TTG AAG-30 (forward) and
50-GCGG AAGCTT CCACC ATG GAT TAC AAG GAT GAC GAC GAT AAG
CCT GGT ATA GCC CAG CAG-30 (reverse), and 50-GCGG CTCGAG TTA CTG
CAG ACG TTC TGA GTT TCC-30 (forward) and 50-GCGG AAGCTT CCACC
ATG GAT TAC AAG GAT GAC GAC GAT AAG GAT CAC AAG ACC ACT CC-30
(reverse), respectively. The plasmid expressing Myc-tagged cIAP2 was ob-
tained from R. Korneluk (University of Ottawa, Canada); Myc-cIAP2-BIR and
Myc-cIAP2-CARD-RING were obtained by PCR subcloning with the following
primers: 50-GCGG AAGCTT CC ACC ATG GAA CAA AAA CTT ATT TCT GAA
GAA GAT CTG GTA GAA AAC AGC ATA TTC-30 (forward) and 50-GCGGC
TCGAGTCA GTCTG ATG TGG ATA GCA GCT G-30 (reverse) and 50-GCGG
AAGCTT CCACC ATG GAA CAA AAA CTT ATT TCT GAA GAA GAT CTG
CAG CTG CTA TCC ACA TCA GAC-30 (forward) and 50-GCGG CTCGAGTC
ATG AAA GAA ATG TAC G-30 (reverse), respectively.
Cell Culture
HEK293T and HT29 cells were maintained in 5% CO2 at 37
C in Dulbecco’s
modified Eagle’s medium (HyClone) and McCoy’s 5A modified medium
(Sigma), respectively, supplemented with 10% fetal calf serum (HyClone),
2 mM L-glutamine, and 100 mg/mL penicillin/streptomycin. siRNA were trans-
fected with lipofectamine 2000 (Invitrogen, cat# 11668-19) and plasmid tran-
sient expression was obtained with either lipofectamine 2000 or calcium phos-
phate transfections. We treated HT29 cells for different time points (0, 15 min,
30 min, 45 min, 1 hr, and 2 hr) with Tri-DAP at 10 mg/mL transfected into the
cells by using the DOTAP cationic lipid transfection reagent in accordance
with the manufacturer’s instructions.
Primary Culture of Bone-Marrow-Derived Macrophages
Femurs and tibias of wild-type (C57BL6), Ripk2/, Birc2/, and Birc3/
mice were flushed with a 25G needle and cold RPMI 1640 (GIBCO) into a
15 mL tube. The suspension was then filtered through a 70 mm cell strainer
and spun for 5 min at 400 g. Pellets were resuspended in complete RPMI
1640 supplemented with 15% L929 cell-conditioned media and plated in
non-cell-culture-treated 10 cm dishes. Cells were cultured at 37C in a 10%
CO2 tissue culture incubator for 5–6 days, with media changed on day 3.
MDP (at 10 or 100 mg/mL) was transfected into cells for different time points
(0, 15 min, 30 min, 45 min, 1 hr, or 2h) with DOTAP according to the manufac-
turer’s instructions.
Quantitative Real-Time PCR
Total RNA was extracted from cells with the Trizol reagent (Invitrogen), and this
was followed by isopropanol precipitation. We reverse-transcribed 2 mg total
RNA to cDNA by using random hexamers and the M-MLV Reverse transcrip-
tase (Invitrogen) in a volume of 20 ml according to the manufacturer’s protocol.
Quantitative RT-PCR primers for different cytokines and chemokines used in
this study are described in Table S1 and S2.
Immunoblotting, Immunoprecipitation, and Pull-Down Experiments
Cells were lysed either directly in Laemmli sample buffer, in RIPA lysis buffer
(10 mM Tris [pH 8.0], 150 mM NaCl, 1% Nonidet P-40, 0.1% SDS, and 0.5%
deoxycholate, supplemented with a protease inhibitor tablet [Roche]), in
NP40 buffer (10 mM Tris [pH 8.0], 150 mM NaCl, and1% Nonidet P-40, supple-
mented with a protease inhibitor tablet [Roche]), or in buffer B150 (20 mM
Tris-HCl [pH 8.0], 150 mM KCl, 10% glycerol, 5 mM MgCl2, and 0.1%).
SDS-polyacrylamide gel electrophoresis and immunoblotting were performed
in accordance with standard protocols. Direct immunoprecipitations were per-
formed in RIPA; coimmunoprecipitations were performed in NP-40 or B150
buffer and pull-down assays were performed in NP40 buffer. Myc-tagged
RIP2 was produced in vitro with a TnT T7 quick coupled transcription and
translation system (Promega Cat# L1170) and GST, GST-cIAP1, and GST-
cIAP2 fusion proteins were produced in bacteria from pGEX4T2 constructs.
Intraperitoneal Injection of MDP and DAP
Wild-type, RIP2, and ciap2-deficient mice were injected intraperitoneally with
2 mg/kg of DAP. Twenty-four hours after injection, infiltrating cells were
collected in PBS by peritoneal lavage, counted, and labeled for 30 min in the
dark with Gr-1 antibodies coupled with Alexa Fluor 488 (Serotec). Gr-1-posi-tive cells were enumerated by FACSCalibur flow cytometery. DAP (2 mg/kg)
or MDP (25 mg/kg) were injected intraperitoneally (i.p.). Blood was collected
by heart puncture 2 hr or 4 hr, respectively, after agonist injection. Serum
was used to quantify IL-6, KC, and MCP-1 levels by bead-based immunoas-
says with a kit from Lincoplex (Millipore).
DSS Colitis
C57BL6, Rip2-deficient, and ciap2-deficient mice were given 4% DSS (MW
36,000-50,000; MP Biomedicals) in drinking water for 6 days (days 0–5) and
then placed on regular water for 3 days (days 6–8). Mice were administered
MDP (100 mg, i.p.) or PBS early during colitis on days 0, 1, and 2. Mice were
monitored daily for body weight loss. Blood was collected by heart puncture
on day 8 and serum was used to quantify serum amyloid A (SAA) levels by
ELISA (Biosource).
Histopathological Analysis and Immunohistochemistry
Colons were fixed in 10% formalin and embedded in paraffin. Serial 5-mm-
thick sections were cut onto glass slides and stained with hematoxylin and
eosin (H&E). Sections were blindly assessed for signs of colitis: tissue
morphology, epithelial erosion, loss of goblet cells, loss of crypts, presence
of inflammatory infiltrate, and thickening of the colon wall.
Statistical Analysis
Two-tailed Student t test was used to evaluate significant differences among
two groups. In Figures 1, 2, and 5, two-tailed Student’s t test was used for
statistical analysis of cytokine and chemokine production comparing the
agonist-treated group of each deficient genotype to the agonist-treated group
of wild-type controls. In Figure 6, two-tailed Student’s t test was used for
statistical analysis of SAA levels, comparing the PBS-treated group to the
MDP-treated group within each genotype. One-way ANOVA was used for
evaluating significant differences among multiple groups in Figure 6A. Two-
tailed Student’s t test was also used to compare PBS-treated group to the
MDP-treated group within each genotype.
SUPPLEMENTAL DATA
Supplemental Data include two figures and two tables and can be found with
this article online at http://www.cell.com/immunity/supplemental/S1074-
7613(09)00203-9.
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